|View printer-friendly version|
Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch
Conference Call Details
The live conference call on
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the
Michele Mantynen Portola Pharmaceuticalsir@portola.com Media Contact: Jacquelyn Matter Pure Communicationsjmatter@purecommunications.com